For research use only. Not for therapeutic Use.
TRV120056 is a biased ligand of the angiotensin II type 1 (AT1) receptor, primarily used in cardiovascular research. Unlike traditional AT1 receptor blockers, TRV120056 selectively activates β-arrestin-mediated signaling pathways while avoiding G protein activation. This biased signaling offers therapeutic advantages, including reducing blood pressure and providing cardioprotective effects, without the vasoconstriction and aldosterone secretion typically associated with full AT1 receptor activation. TRV120056 is being investigated for its potential to treat heart failure, hypertension, and other cardiovascular diseases, offering a novel approach that enhances therapeutic outcomes while minimizing common side effects seen with conventional AT1 receptor antagonists.
| Catalog Number | I007973 |
| CAS Number | 40678-47-5 |
| Synonyms | (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-(carboxymethylcarbamoyl)pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid |
| Molecular Formula | C43H65N13O12 |
| Purity | ≥95% |
| InChI | InChI=1S/C43H65N13O12/c1-5-23(4)35(41(67)53-30(17-25-19-47-21-50-25)42(68)56-15-7-9-31(56)39(65)49-20-33(60)61)55-38(64)29(16-24-10-12-26(57)13-11-24)52-40(66)34(22(2)3)54-37(63)28(8-6-14-48-43(45)46)51-36(62)27(44)18-32(58)59/h10-13,19,21-23,27-31,34-35,57H,5-9,14-18,20,44H2,1-4H3,(H,47,50)(H,49,65)(H,51,62)(H,52,66)(H,53,67)(H,54,63)(H,55,64)(H,58,59)(H,60,61)(H4,45,46,48)/t23-,27-,28-,29-,30-,31-,34-,35-/m0/s1 |
| InChIKey | LHGCUVPUBNGERS-FVSPLASQSA-N |
| SMILES | CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NCC(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N |
